Sign in
CompletedNo phase

The Effect of NP-2006 on Sleep Quality and Health

Key facts

Who runs it
Hanpoong Nature Pharm Co., Ltd.
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
48 people enrolled
Started
12 May 2023
Ended
13 Aug 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NP-2006
  • Placebo
Record updated
27 March 2026

Who can take part

Age
19 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Those who agreed to participate in this study and signed a written consent form
  • Adults aged 19 to 65 years, male or female
  • Those with poor sleep quality (PSQI score > 5 points)

Who cannot take part

  • Those taking medications (corticosteroids, psychotropic medications, etc.) that could affect sleep within 1 month of the first visit or expected to take them during the study participation
  • Those receiving hormone therapy
  • Those with the following conditions:; Snoring, sleep apnea, restless legs syndrome, periodic limb movement disorder (PLMD), depression, narcolepsy, or respiratory disease that cause sleep disturbances; Itching, nocturia, chronic pain, or muscle cramps that affect sleep; Uncontrolled diabetes or hypertension
  • Those who are hypersensitive to ingredients in the test or control foods or have experienced severe food allergies
  • Those with severe sleep disturbances (ISI ≥ 22 points)
  • Those with severe daytime sleepiness (ESS ≥ 16 points)
  • Those experiencing changes that could cause excessive stress within 2 weeks of the first visit: death of a spouse, family discord, lawsuits/disputes, sudden financial difficulties, immigration, etc
  • Those who regularly consume excessive alcohol; Men > 210 g/week (approximately 4 bottles of soju/week, approximately 4 glasses/day); Women > 140 g/week (approximately 2.5 bottles of soju/week, approximately 2.5 glasses/day)
  • Those who smoke excessively (> 10 cigarettes/day) or show withdrawal symptoms
  • Those who consume excessive amounts of caffeine (> 3 cups/day)
  • Those who work night shifts or have irregular bedtimes due to their job
  • Those who have traveled or plan to travel long distances to a country with a different time zone within 1 month of the first visit
  • Those with a BMI of 18 kg/m2 or less or 35 kg/m2 or more
  • Those who have continuously taken herbal medicines or health functional foods that may affect sleep within 1 month of the first visit
  • Those who have participated in a clinical trial within 1 month of the first visit
  • Those who are pregnant or lactating, or who are planning to become pregnant
  • Those who the researcher deems unsuitable for participation in this study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective will be to assess the effect of NP-2006 on sleep efficiency in volunteers presented with persistent subclinical insomnia

The 2 groups in the trial

  • Sequence A (NP-2006 first, then Placebo)Treatment being tested

    Group that took tablets containing 500mg of NP-2006 (NP-2006, crystalline cellulose, tapioca starch, hydroxypropylmethylcellulose, etc.) 30 to 60 minutes before going to sleep

    Treatment: NP-2006 and Placebo

  • Sequence B (Placebo first, then NP-2006)Placebo, for comparison

    Group that took tablets not containing NP-2006 (crystalline cellulose, maltodextrin, lactose mixed powder, hydroxypropylmethylcellulose, etc.) 30 to 60 minutes before bedtime

    Treatment: NP-2006 and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of NP-2006 on Sleep Efficiency and Quality in Healthy Volunteers With Persistent Subclinical Insomnia
Record updated
27 March 2026